Rare diseases
Investigational molecules
Locations
Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs
BelgiumA Phase 2a Study of Empasiprubart IV Monotherapy in Adults with AChR‑Ab Seropositive Generalized Myasthenia Gravis
BelgiumA study to evaluate the safety and effectiveness of empasiprubart and efgartigimod alfa in patients with generalized myasthenia gravis.
BelgiumA Study Comparing Nipocalimab and Efgartigimod for Adults with Generalized Myasthenia Gravis
AustriaStudy of efgartigimod given by IV infusion in adolescents aged 12-17 years with chronic immune thrombocytopenia
FranceStudy on the Effectiveness and Safety of Efgartigimod PH20 SC for Adults with Systemic Sclerosis
BelgiumStudy on the Effectiveness and Safety of Efgartigimod IV for Adults with Primary Immune Thrombocytopenia
AustriaStudy on Efgartigimod for Early Treatment in Patients with Generalized Myasthenia Gravis
SpainStudy of Efgartigimod PH20 SC for Children Aged 2 to 17 with Generalized Myasthenia Gravis
BelgiumStudy on the Long-term Safety of Efgartigimod for Children with Generalized Myasthenia Gravis
AustriaStudy on Efgartigimod for Children Aged 2-17 with Generalized Myasthenia Gravis
BelgiumStudy on Long-term Safety and Efficacy of Efgartigimod PH20 SC in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
AustriaTell us about your condition – we search every trial in Europe and connect you with the right site.
